This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

11 Mar 2011

NICE Rejects Two Cancer Drugs

NICE, a UK health watchdog, has rejected two cancer drugs that it was hoped would be made available on the NHS.

The National Institute for Health and Clinical Excellence (NICE) has not recommended Roche's erlotinib (Tarceva), a maintenance treatment for patients with non-small cell lung cancer, and Pierre-Fabre’s vinflunine (Javlor) for sufferers of advanced bladder cancer.


NICE did not find enough evidence to suggest that Tarceva contributes to the extension of life, despite it being approved by the FDA in April 2010.


NICE chief executive Sir Andrew Dillon said, "We have already recommended pemetrexed as a maintenance treatment under certain circumstances and are disappointed not to have been able to recommend erlotinib.

Related News